{"id":"https://openalex.org/W2000007859","doi":"https://doi.org/10.1517/14728222.2015.1009448","title":"Targeting \u03b1-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies","display_name":"Targeting \u03b1-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies","publication_year":2015,"publication_date":"2015-03-18","ids":{"openalex":"https://openalex.org/W2000007859","doi":"https://doi.org/10.1517/14728222.2015.1009448","mag":"2000007859","pmid":"https://pubmed.ncbi.nlm.nih.gov/25785645","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4608017"},"language":"en","primary_location":{"id":"doi:10.1517/14728222.2015.1009448","doi":"https://doi.org/10.1517/14728222.2015.1009448","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14728222.2015.1009448","pdf_url":null,"source":{"id":"https://openalex.org/S149756942","display_name":"Expert Opinion on Therapeutic Targets","issn_l":"1472-8222","issn":["1472-8222","1744-7631"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Therapeutic Targets","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4608017","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090369580","display_name":"Simon Moussaud","orcid":"https://orcid.org/0000-0002-6340-9511","observed_orcids":["https://orcid.org/0000-0002-6340-9511"]},"institutions":[{"id":"https://openalex.org/I4210146710","display_name":"Mayo Clinic in Florida","ror":"https://ror.org/03zzw1w08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simon Moussaud","raw_affiliation_strings":["Mayo Clinic Florida, Neuroscience, 4500 San Pablo road, Jacksonville, 32224, FL, USA McLean.Pamela@mayo.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Florida, Neuroscience, 4500 San Pablo road, Jacksonville, 32224, FL, USA McLean.Pamela@mayo.edu","institution_ids":["https://openalex.org/I4210146710"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029970248","display_name":"Siobhan Malany","orcid":"https://orcid.org/0000-0003-0710-7460","observed_orcids":["https://orcid.org/0000-0003-0710-7460"]},"institutions":[{"id":"https://openalex.org/I188891513","display_name":"Sanford Burnham Prebys Medical Discovery Institute","ror":"https://ror.org/03m1g2s55","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I188891513"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Siobhan Malany","raw_affiliation_strings":["Sanford-Burnham Medical Research Institute, The Conrad Prebys Center for Chemical Genomics, Lake Nona, Orlando, 32827, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanford-Burnham Medical Research Institute, The Conrad Prebys Center for Chemical Genomics, Lake Nona, Orlando, 32827, FL, USA","institution_ids":["https://openalex.org/I188891513"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006777013","display_name":"Alka Mehta","orcid":"https://orcid.org/0000-0002-4417-8041","observed_orcids":["https://orcid.org/0000-0002-4417-8041"]},"institutions":[{"id":"https://openalex.org/I188891513","display_name":"Sanford Burnham Prebys Medical Discovery Institute","ror":"https://ror.org/03m1g2s55","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I188891513"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alka Mehta","raw_affiliation_strings":["Sanford-Burnham Medical Research Institute, The Conrad Prebys Center for Chemical Genomics, Lake Nona, Orlando, 32827, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanford-Burnham Medical Research Institute, The Conrad Prebys Center for Chemical Genomics, Lake Nona, Orlando, 32827, FL, USA","institution_ids":["https://openalex.org/I188891513"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034968976","display_name":"Stefan Vasile","orcid":"https://orcid.org/0000-0002-2679-7156","observed_orcids":["https://orcid.org/0000-0002-2679-7156"]},"institutions":[{"id":"https://openalex.org/I188891513","display_name":"Sanford Burnham Prebys Medical Discovery Institute","ror":"https://ror.org/03m1g2s55","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I188891513"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan Vasile","raw_affiliation_strings":["Sanford-Burnham Medical Research Institute, The Conrad Prebys Center for Chemical Genomics, Lake Nona, Orlando, 32827, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanford-Burnham Medical Research Institute, The Conrad Prebys Center for Chemical Genomics, Lake Nona, Orlando, 32827, FL, USA","institution_ids":["https://openalex.org/I188891513"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019646154","display_name":"Layton Harris Smith","orcid":"https://orcid.org/0000-0003-2621-9740","observed_orcids":["https://orcid.org/0000-0003-2621-9740"]},"institutions":[{"id":"https://openalex.org/I188891513","display_name":"Sanford Burnham Prebys Medical Discovery Institute","ror":"https://ror.org/03m1g2s55","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I188891513"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Layton H Smith","raw_affiliation_strings":["Sanford-Burnham Medical Research Institute, The Conrad Prebys Center for Chemical Genomics, Lake Nona, Orlando, 32827, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanford-Burnham Medical Research Institute, The Conrad Prebys Center for Chemical Genomics, Lake Nona, Orlando, 32827, FL, USA","institution_ids":["https://openalex.org/I188891513"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000693728","display_name":"Pamela J. McLean","orcid":"https://orcid.org/0000-0003-4870-5715","observed_orcids":["https://orcid.org/0000-0003-4870-5715","https://orcid.org/0000-0003-3168-951X"]},"institutions":[{"id":"https://openalex.org/I4210146710","display_name":"Mayo Clinic in Florida","ror":"https://ror.org/03zzw1w08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Pamela J McLean","raw_affiliation_strings":["Mayo Clinic Florida, Neuroscience, 4500 San Pablo road, Jacksonville, 32224, FL, USA McLean.Pamela@mayo.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Florida, Neuroscience, 4500 San Pablo road, Jacksonville, 32224, FL, USA McLean.Pamela@mayo.edu","institution_ids":["https://openalex.org/I4210146710"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5000693728"],"corresponding_institution_ids":["https://openalex.org/I4210146710"],"apc_list":null,"apc_paid":null,"fwci":2.1151,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":{"value":0.86081744,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"19","issue":"5","first_page":"589","last_page":"603"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11266","display_name":"Neuroinflammation and Neurodegeneration Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alpha-synuclein-oligomers","display_name":"alpha-synuclein oligomers","score":0.9539999961853027},{"id":"https://openalex.org/keywords/protein-fragment-complementation","display_name":"protein fragment complementation","score":0.9190000295639038},{"id":"https://openalex.org/keywords/synucleinopathies","display_name":"synucleinopathies","score":0.9259999990463257},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dementia-with-lewy-bodies","display_name":"dementia with Lewy bodies","score":1.0},{"id":"https://openalex.org/keywords/alpha-synuclein-oligomerization","display_name":"alpha-synuclein oligomerization","score":0.8989999890327454},{"id":"https://openalex.org/keywords/p38-mapk-inhibitor","display_name":"p38 MAPK inhibitor","score":0.7860000133514404},{"id":"https://openalex.org/keywords/high-throughput-screening","display_name":"high-throughput screening","score":0.7929999828338623},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.7319999933242798},{"id":"https://openalex.org/keywords/protein-aggregation","display_name":"protein aggregation","score":0.5789999961853027}],"concepts":[{"id":"https://openalex.org/C2777440831","wikidata":"https://www.wikidata.org/wiki/Q2376264","display_name":"Synucleinopathies","level":5,"score":0.9163191318511963},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.7715563774108887},{"id":"https://openalex.org/C115867849","wikidata":"https://www.wikidata.org/wiki/Q753175","display_name":"Protein-fragment complementation assay","level":5,"score":0.5241361260414124},{"id":"https://openalex.org/C2778548049","wikidata":"https://www.wikidata.org/wiki/Q101245788","display_name":"Dementia with Lewy bodies","level":4,"score":0.5183361768722534},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.4973020851612091},{"id":"https://openalex.org/C2781449126","wikidata":"https://www.wikidata.org/wiki/Q288591","display_name":"Alpha-synuclein","level":4,"score":0.4960518777370453},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4319964647293091},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.41759246587753296},{"id":"https://openalex.org/C188082640","wikidata":"https://www.wikidata.org/wiki/Q1780899","display_name":"Complementation","level":4,"score":0.385659784078598},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.365420401096344},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.33268463611602783},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.25456905364990234},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.20289334654808044},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.1692308485507965},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.12783294916152954},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C127716648","wikidata":"https://www.wikidata.org/wiki/Q104053","display_name":"Phenotype","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020961","descriptor_name":"Lewy Body Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D020961","descriptor_name":"Lewy Body Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D020961","descriptor_name":"Lewy Body Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D020961","descriptor_name":"Lewy Body Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D020961","descriptor_name":"Lewy Body Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D020961","descriptor_name":"Lewy Body Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D047390","descriptor_name":"Casein Kinase II","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D047390","descriptor_name":"Casein Kinase II","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D047390","descriptor_name":"Casein Kinase II","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D048051","descriptor_name":"p38 Mitogen-Activated Protein Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D048051","descriptor_name":"p38 Mitogen-Activated Protein Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D048051","descriptor_name":"p38 Mitogen-Activated Protein Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051844","descriptor_name":"alpha-Synuclein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051844","descriptor_name":"alpha-Synuclein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051844","descriptor_name":"alpha-Synuclein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D055503","descriptor_name":"Protein Multimerization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055503","descriptor_name":"Protein Multimerization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055503","descriptor_name":"Protein Multimerization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D057166","descriptor_name":"High-Throughput Screening Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057166","descriptor_name":"High-Throughput Screening Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057166","descriptor_name":"High-Throughput Screening Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1517/14728222.2015.1009448","doi":"https://doi.org/10.1517/14728222.2015.1009448","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14728222.2015.1009448","pdf_url":null,"source":{"id":"https://openalex.org/S149756942","display_name":"Expert Opinion on Therapeutic Targets","issn_l":"1472-8222","issn":["1472-8222","1744-7631"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Therapeutic Targets","raw_type":"journal-article"},{"id":"pmid:25785645","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25785645","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on therapeutic targets","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4608017","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4608017","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Expert Opin Ther Targets","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:4608017","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4608017","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Expert Opin Ther Targets","raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9476000070571899}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.5199999809265137}],"study_designs":[],"awards":[{"id":"https://openalex.org/G249548837","display_name":null,"funder_award_id":"NS063963","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"},{"id":"https://openalex.org/G3949585732","display_name":"Extracellular alpha-synuclein in Parkinson's Disease","funder_award_id":"R01NS073740","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"},{"id":"https://openalex.org/G5273106241","display_name":"Role of oligomeric alpha-synuclein in synucleinopathies","funder_award_id":"R01NS063963","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"}],"funders":[{"id":"https://openalex.org/F4320306143","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03"},{"id":"https://openalex.org/F4320337359","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":58,"referenced_works":["https://openalex.org/W1496790952","https://openalex.org/W1511705190","https://openalex.org/W1515692648","https://openalex.org/W1527671059","https://openalex.org/W1588992473","https://openalex.org/W1811548175","https://openalex.org/W1834766425","https://openalex.org/W1965169361","https://openalex.org/W1965778124","https://openalex.org/W1965888147","https://openalex.org/W1976316003","https://openalex.org/W1979786105","https://openalex.org/W1997417422","https://openalex.org/W1997524825","https://openalex.org/W2004109773","https://openalex.org/W2005622137","https://openalex.org/W2015913654","https://openalex.org/W2017196830","https://openalex.org/W2021977313","https://openalex.org/W2031982078","https://openalex.org/W2034210468","https://openalex.org/W2034887565","https://openalex.org/W2037262355","https://openalex.org/W2039425688","https://openalex.org/W2047206971","https://openalex.org/W2052098570","https://openalex.org/W2056865885","https://openalex.org/W2060842568","https://openalex.org/W2069491212","https://openalex.org/W2073852487","https://openalex.org/W2074649216","https://openalex.org/W2075654975","https://openalex.org/W2077196709","https://openalex.org/W2082359973","https://openalex.org/W2087389265","https://openalex.org/W2090905739","https://openalex.org/W2091265794","https://openalex.org/W2091586455","https://openalex.org/W2092293417","https://openalex.org/W2092791231","https://openalex.org/W2098004479","https://openalex.org/W2100817247","https://openalex.org/W2108865709","https://openalex.org/W2110076327","https://openalex.org/W2114835861","https://openalex.org/W2120867735","https://openalex.org/W2123089419","https://openalex.org/W2123431154","https://openalex.org/W2125447215","https://openalex.org/W2133272695","https://openalex.org/W2139506875","https://openalex.org/W2150656456","https://openalex.org/W2154737306","https://openalex.org/W2157102136","https://openalex.org/W2157155969","https://openalex.org/W2172185016","https://openalex.org/W2178984859","https://openalex.org/W4296930794"],"related_works":["https://openalex.org/W2116688789","https://openalex.org/W6925975906","https://openalex.org/W4255428316","https://openalex.org/W3117762269","https://openalex.org/W7096912881","https://openalex.org/W2999576498","https://openalex.org/W3115081643","https://openalex.org/W2299408552","https://openalex.org/W4321445874","https://openalex.org/W4312095508"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Reducing":[1],"the":[2,27,59,97,112,130,138,153],"burden":[3],"of":[4,29,61,114,132,140,152],"\u03b1-synuclein":[5,37,77,86,141,159],"oligomeric":[6],"species":[7],"represents":[8],"a":[9,41,118,123],"promising":[10],"approach":[11],"for":[12,89,137,173],"disease-modifying":[13,174],"therapies":[14,175],"against":[15,176],"synucleinopathies":[16,177],"such":[17],"as":[18],"Parkinson's":[19],"disease":[20],"and":[21,122,178],"dementia":[22],"with":[23,165],"Lewy":[24],"bodies.":[25],"However,":[26],"lack":[28],"efficient":[30],"drug":[31,44,170],"discovery":[32,45,171],"strategies":[33],"that":[34,57],"specifically":[35],"target":[36],"oligomers":[38],"has":[39],"been":[40],"limitation":[42],"to":[43,65,75,157],"programs.":[46],"RESEARCH":[47],"DESIGN":[48],"AND":[49],"METHODS:":[50],"Here":[51],"we":[52],"describe":[53],"an":[54],"innovative":[55],"strategy":[56,154],"harnesses":[58],"power":[60],"bimolecular":[62],"protein-fragment":[63,94,134],"complementation":[64,95,135],"monitor":[66,76,158],"synuclein-synuclein":[67],"interactions.":[68],"We":[69],"have":[70],"developed":[71],"two":[72,115],"robust":[73],"models":[74],"oligomerization":[78,142],"by":[79],"generating":[80],"novel":[81],"stable":[82],"cell":[83],"lines":[84],"expressing":[85],"fusion":[87],"proteins":[88],"either":[90],"fluorescent":[91],"or":[92],"bioluminescent":[93],"under":[96],"tetracycline-controlled":[98],"transcriptional":[99],"activation":[100],"system.":[101],"MAIN":[102],"OUTCOME":[103],"MEASURES:":[104],"A":[105],"pilot":[106],"screen":[107],"was":[108],"performed":[109],"resulting":[110],"in":[111,143,162],"identification":[113],"potential":[116],"hits,":[117],"p38":[119],"MAPK":[120],"inhibitor":[121],"casein":[124],"kinase":[125],"2":[126],"inhibitor,":[127],"thereby":[128],"demonstrating":[129],"suitability":[131],"our":[133],"assay":[136],"measurement":[139],"living":[144,163],"cells":[145,164],"at":[146],"high":[147,166],"throughput.":[148],"CONCLUSIONS:":[149],"The":[150],"application":[151],"described":[155],"herein":[156],"oligomer":[160],"formation":[161],"throughput":[167],"will":[168],"facilitate":[169],"efforts":[172],"other":[179],"proteinopathies.":[180]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}